ClinicalTrials.gg
CompletedNCT05248997Updated Mar 26, 2025Results posted

Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis

A Phase 3 interventional study of rimegepant 75 mg ODT and Matching placebo in Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps, sponsored by Pfizer. Completed at 33 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-26.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
261
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Nasal Polyps with a site in United States — 13 open to participants now, 20 under way, 8 of them phase 3. Nasal Polyps · United States.

Enrollment
14th of 71
261 · median 60
Started
2022
with 5 others
Phase 3
25 of 83
4 open now
Registered
58th of 83
by date

Among the 83 studies in Nasal Polyps with a site in United States, this one is the 14th largest by enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2022, is one of 25 in phase 3, and was the 58th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

13 of the 83 studies in Nasal Polyps with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Nasal Polyps with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of rimegepant versus placebo in the acute treatment of chronic rhinosinusitis (CRS) with and without nasal polyps.

03

Conditions studied

  • Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

Keywords

  • Chronic Rhinosinusitis (CRS)
  • Chronic Rhinosinusitis (CRS) with Nasal Polyps
  • Chronic Rhinosinusitis (CRS) without Nasal Polyps
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least two episodes of facial pain/pressure/fullness of moderate or severe intensity on a 4-point rating scale (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) in the past 30 days prior to the Screening Visit.
  • Subject agrees to study-required medication restrictions and the restriction of not starting new medication to treat CRS symptoms during the course of the study.
  • Subject agrees to study-required methods during the course of the study, and female subjects must not be breastfeeding.
  • No abnormality identified on the medical or laboratory evaluation.

Exclusion criteria

Exclusion Criteria:

  • Subject has primary headache disorder.
  • Subject has history of nasal or facial surgery within the 6 months prior to screening.
  • Subject has ongoing rhinitis medicamentosa.
  • Subject has diagnosed or suspected invasive fungal rhinosinusitis.
  • Subject is currently receiving aspirin desensitization or maintenance therapy for Samter's Triad.
  • Subject has a history of recurrent acute sinusitis (four or more episodes per year of acute bacterial rhinosinusitis (ABRS) without signs or symptoms of rhinosinusitis between episodes).
  • > 35.0kg/m2
  • Subject history of exclusionary medical conditions such as disease, cardiovascular conditions, uncontrolled hypertension or diabetes, psychiatric conditions, drug or alcohol abuse, , drug allergies, or any significant and/or unstable medical conditions.
  • Subjects taking/using excluded therapies.
  • Participation in clinical trial with non-biological agents or investigational interventional treatments.
  • Subjects who have previously participated in any BHV-3000/ BMS-927711/ rimegepant study.
  • Planned participation in any other investigational clinical trial while participating in this clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
261 participants (actual)

Study arms

  • Active comparator
    rimegepant 75 mg ODT

    One dose of rimegepant 75 mg ODT

    Drug: rimegepant 75 mg ODT

  • Active comparator
    Matching Placebo

    One dose of matching placebo

    Drug: Matching placebo

Interventions

  • One dose of rimegepant 75 mg ODT

  • DrugMatching placebo

    One dose of matching placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Facial Pain/Pressure/Fullness on NRS at 2 Hours Post-Dose

    Facial pain/pressure/fullness was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no facial pain/pressure/fullness" and 10 being "worst imaginable facial pain/pressure/fullness." Higher scores signified worse condition.

    Time frame: Baseline, 2 hours post-dose

Secondary outcomes

  1. Change From Baseline in Total Nasal Symptom Score (TNSS) at 2 Hours Post-Dose

    TNSS was calculated as the sum of 3 symptom scores: facial pain/pressure/fullness, score ranged from 0 (no facial pain/pressure/fullness) to 10 (worst imaginable facial pain/pressure/fullness); nasal obstruction (congestion), score ranged from 0 (no nasal obstruction (congestion) to 10 (worst imaginable nasal obstruction (congestion); and nasal discharge, score ranged from 0 (no nasal discharge) to 10 (worst nasal discharge). TNSS overall score ranged from 0 (no nasal symptom) to 30 (worst nasal symptom); higher scores signified worse condition.

    Time frame: Baseline, 2 hours post-dose

  2. Change From Baseline in Nasal Obstruction (Congestion) at 2 Hours Post-Dose

    Nasal obstruction (congestion) severity was assessed using a NRS ranging in integers from 0 (no nasal obstruction \[congestion\]) to 10 (worst imaginable nasal obstruction \[congestion\]). Higher scores signified worse condition.

    Time frame: Baseline, 2 hours post-dose

  3. Change From Baseline in Nasal Discharge at 2 Hours Post-Dose

    Nasal discharge severity was assessed using a NRS ranging in integers from 0 (no nasal discharge) to 10 (worst imaginable nasal discharge). Higher scores signified worse condition.

    Time frame: Baseline, 2 hours post-dose

  4. Percentage of Participants With Headache Pain Relief at 2 Hours Post-Dose

    Headache pain relief was defined as a headache pain level of none or mild at 2 hours post-dose on a 4-point Likert scale (0 = None; 1 = Mild; 2 = Moderate; 3 = Severe).

    Time frame: 2 hours post-dose

  5. Percentage of Participants Who Used Rescue Medication Within 24 Hours Post-dose

    Post 2 hours after dosing with study medication and after the 2-hour assessments were completed on the e-diary, participants were permitted to use the following rescue medications (non-study medications) such as: acetaminophen or aspirin, ibuprofen, naproxen (or any other type of nonsteroidal anti-inflammatory drug \[NSAID\]), oral antihistamines (non- sedating), oral decongestants, topical nasal decongestants, topical nasal anticholinergics.

    Time frame: Through 24 hours post-dose

07

Results

Posted Mar 26, 2025

Participant flow

A total of 261 participants were enrolled and randomized in the study. Amongst which 99 received rimegepant and 105 received placebo.

Participant flow — Overall Study
MilestoneRimegepant 75 mgPlacebo
Started131130
Treated99105
Completed98104
Not completed3326
Withdrew: Lost to follow-up11
Withdrew: Randomized but not treated3225

Outcome measures

PrimaryChange From Baseline in Facial Pain/Pressure/Fullness on NRS at 2 Hours Post-Dose

Facial pain/pressure/fullness was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no facial pain/pressure/fullness" and 10 being "worst imaginable facial pain/pressure/fullness." Higher scores signified worse condition.

Time frame:
Baseline, 2 hours post-dose
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Facial Pain/Pressure/Fullness on NRS at 2 Hours Post-Dose
Scores on a scaleRimegepant 75 mgPlacebo
Change From Baseline in Facial Pain/Pressure/Fullness on NRS at 2 Hours Post-Dose-2.70 (-3.16 to -2.25)-2.61 (-3.06 to -2.17)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Linear model (LM) · p = 0.7782 (LM included baseline value as covariate,\& fixed effects for treatment group,stratification factor,scheduled time point(TP),TP by treatment group interaction.Repeated measures:modelled by unstructured covariance structure for within participant error.) · Difference in least square mean: -0.09 · 95% CI -0.71 to 0.53
SecondaryChange From Baseline in Total Nasal Symptom Score (TNSS) at 2 Hours Post-Dose

TNSS was calculated as the sum of 3 symptom scores: facial pain/pressure/fullness, score ranged from 0 (no facial pain/pressure/fullness) to 10 (worst imaginable facial pain/pressure/fullness); nasal obstruction (congestion), score ranged from 0 (no nasal obstruction (congestion) to 10 (worst imaginable nasal obstruction (congestion); and nasal discharge, score ranged from 0 (no nasal discharge) to 10 (worst nasal discharge). TNSS overall score ranged from 0 (no nasal symptom) to 30 (worst nasal symptom); higher scores signified worse condition.

Time frame:
Baseline, 2 hours post-dose
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Total Nasal Symptom Score (TNSS) at 2 Hours Post-Dose
Scores on a scaleRimegepant 75 mgPlacebo
Change From Baseline in Total Nasal Symptom Score (TNSS) at 2 Hours Post-Dose-7.04 (-8.16 to -5.91)-6.74 (-7.85 to -5.64)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Linear model (LM) · p = 0.7079 (LM included baseline value as covariate, and fixed effects for treatment group,stratification factor,scheduled TP, TP by treatment group interaction.Repeated measures:modelled by unstructured covariance structure for within participant error.) · Difference in least square mean: -0.29 · 95% CI -1.83 to 1.24
SecondaryChange From Baseline in Nasal Obstruction (Congestion) at 2 Hours Post-Dose

Nasal obstruction (congestion) severity was assessed using a NRS ranging in integers from 0 (no nasal obstruction \[congestion\]) to 10 (worst imaginable nasal obstruction \[congestion\]). Higher scores signified worse condition.

Time frame:
Baseline, 2 hours post-dose
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Nasal Obstruction (Congestion) at 2 Hours Post-Dose
Scores on a scaleRimegepant 75 mgPlacebo
Change From Baseline in Nasal Obstruction (Congestion) at 2 Hours Post-Dose-2.48 (-2.91 to -2.05)-2.25 (-2.67 to -1.82)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Linear model (LM) · p = 0.4398 (LM included baseline value as covariate, and fixed effects for treatment group,stratification factor,scheduled TP, TP by treatment group interaction.Repeated measures:modelled by unstructured covariance structure for within participant error.) · Difference in least square mean: -0.23 · 95% CI -0.81 to 0.36
SecondaryChange From Baseline in Nasal Discharge at 2 Hours Post-Dose

Nasal discharge severity was assessed using a NRS ranging in integers from 0 (no nasal discharge) to 10 (worst imaginable nasal discharge). Higher scores signified worse condition.

Time frame:
Baseline, 2 hours post-dose
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Nasal Discharge at 2 Hours Post-Dose
Scores on a scaleRimegepant 75 mgPlacebo
Change From Baseline in Nasal Discharge at 2 Hours Post-Dose-1.81 (-2.22 to -1.41)-1.85 (-2.25 to -1.45)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Linear model (LM) · p = 0.8890 (LM included baseline value as covariate, and fixed effects for treatment group,stratification factor,scheduled TP, TP by treatment group interaction.Repeated measures:modelled by unstructured covariance structure for within participant error.) · Difference in least square mean: 0.04 · 95% CI -0.51 to 0.59
SecondaryPercentage of Participants With Headache Pain Relief at 2 Hours Post-Dose

Headache pain relief was defined as a headache pain level of none or mild at 2 hours post-dose on a 4-point Likert scale (0 = None; 1 = Mild; 2 = Moderate; 3 = Severe).

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of Participants
Percentage of Participants With Headache Pain Relief at 2 Hours Post-Dose
Percentage of ParticipantsRimegepant 75 mgPlacebo
Percentage of Participants With Headache Pain Relief at 2 Hours Post-Dose59.4 (47.8 to 71.0)55.6 (44.7 to 66.4)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Mantel-Haenszel · p = 0.6412 · Percentage difference: 3.8 · 95% CI -12.1 to 19.7Stratified by presence of nasal polyps at randomization with Mantel-Haenszel risk estimation.
SecondaryPercentage of Participants Who Used Rescue Medication Within 24 Hours Post-dose

Post 2 hours after dosing with study medication and after the 2-hour assessments were completed on the e-diary, participants were permitted to use the following rescue medications (non-study medications) such as: acetaminophen or aspirin, ibuprofen, naproxen (or any other type of nonsteroidal anti-inflammatory drug \[NSAID\]), oral antihistamines (non- sedating), oral decongestants, topical nasal decongestants, topical nasal anticholinergics.

Time frame:
Through 24 hours post-dose
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Used Rescue Medication Within 24 Hours Post-dose
Percentage of ParticipantsRimegepant 75 mgPlacebo
Percentage of Participants Who Used Rescue Medication Within 24 Hours Post-dose7.3 (2.1 to 12.5)10.0 (4.1 to 15.9)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Mantel-Haenszel · p = 0.5001 · Percentage difference: -2.7 · 95% CI -10.6 to 5.2Stratified by presence of nasal polyps at randomization with Mantel-Haenszel risk estimation.

Adverse events

Collected over Within 7 (+2) days post single administration of study medication (single dose was to be administered on any day from randomization to 45 days post randomization). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rimegepant0/99 (0%)0/99 (0%)4/99 (4%)
Placebo0/105 (0%)0/105 (0%)5/105 (4.8%)
Most frequent other events
Most frequent other events
EventRimegepantPlacebo
Aspartate aminotransferase increasedInvestigations1/990/105
Blood creatine phosphokinase increasedInvestigations1/990/105
Upper respiratory tract infectionInfections and infestations1/990/105
Head injuryInjury, poisoning and procedural complications1/990/105
Dry throatRespiratory, thoracic and mediastinal disorders1/990/105
DiarrhoeaGastrointestinal disorders0/991/105
NauseaGastrointestinal disorders0/991/105
Electrocardiogram PR shortenedInvestigations0/991/105
HypertransaminasaemiaHepatobiliary disorders0/991/105
Back painMusculoskeletal and connective tissue disorders0/991/105

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Rimegepant 75 mgPlaceboTotal
Mean48.6 ± 15.2749.9 ± 15.8349.3 ± 15.53
Sex: Female, Male
Sex: Female, Male(Participants)Rimegepant 75 mgPlaceboTotal
Female7768145
Male5462116
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rimegepant 75 mgPlaceboTotal
Hispanic or Latino273663
Not Hispanic or Latino10293195
Unknown or Not Reported213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rimegepant 75 mgPlaceboTotal
American Indian or Alaska Native000
Asian415
Native Hawaiian or Other Pacific Islander011
Black or African American191736
White106105211
More than one race033
Unknown or Not Reported235
08

Study locations

33 sites
  • San Diego Clinical Research Center
    La Mesa, California 91942, United States
  • Velocity Clinical San Diego
    La Mesa, California 91942, United States
  • National Research Institute
    Panorama City, California 91402, United States
  • Sacramento Ear Nose and Throat Surgical and Medical Group, Inc.
    Roseville, California 95628, United States
  • Sharp & Children's MRI Center, LLC (CT scan)
    San Diego, California 92123, United States
  • Breathe Clear Institute
    Torrance, California 90503, United States
  • Colorado ENT & Allergy
    Colorado Springs, Colorado 80923, United States
  • Velocity Clinical Research, New Smyrna Beach
    Edgewater, Florida 32132, United States
  • The Medici Medical Research, LLC
    Hollywood, Florida 33021, United States
  • Avantis Clinical Research
    Miami, Florida 33155, United States
  • Clinovation Research
    Pompano Beach, Florida 33064, United States
  • Treasure Valley Medical Research
    Boise, Idaho 83706, United States
  • ChicagoENT
    Chicago, Illinois 60657, United States
  • Kentuckiana Ear, Nose & Throat
    Louisville, Kentucky 40205, United States
  • Best Clinical Trials, LLC (Administrative Only)
    New Orleans, Louisiana 70115, United States
  • George Stanley Walker, MD
    New Orleans, Louisiana 70115, United States
  • University of Missouri Hospital & Clinics, ENT & Allergy Center of Missouri
    Columbia, Missouri 65201, United States
  • University of Missouri Healthcare - Investigational Pharmacy
    Columbia, Missouri 65212, United States
  • University of Missouri Hospital (Radiology)
    Columbia, Missouri 65212, United States
  • Clinvest Research, LLC
    Springfield, Missouri 65810, United States
  • St Charles Clinical Research
    Weldon Spring, Missouri 63304, United States
  • Northwell Health Department of Otolaryngology
    New Hyde Park, New York 11042, United States
  • Tekton Research, Inc.
    Edmond, Oklahoma 73013, United States
  • Allergy, Asthma & Clinical Research Center
    Oklahoma City, Oklahoma 73120, United States
  • Vital Prospects Clinical Research Institute, P.C.
    Tulsa, Oklahoma 74136, United States
  • Velocity Clinical Research, Grants Pass
    Grants Pass, Oregon 97527, United States
  • Velocity Clinical Research, Medford
    Medford, Oregon 97504, United States
  • Velocity Clinical Research, Anderson
    Anderson, South Carolina 29621, United States
  • Carolina ENT Clinic/CENTRI Inc.
    Orangeburg, South Carolina 29118, United States
  • Spokane Ear, Nose & Throat/ Columbia Surgical Specialists
    Spokane, Washington 99201, United States
  • Principle Research Solutions
    Spokane, Washington 99204, United States
  • Spokane Ear, Nose & Throat / Columbia Surgical Specialists
    Spokane, Washington 99216, United States
  • Allergy, Asthma & Sinus Center, S.C.
    Greenfield, Wisconsin 53228, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Mar 2024, 24 months.

Results were first posted in Mar 2025, 1 year after primary completion.

Of 30 industry-sponsored phase 3 interventional studies under Nasal Polyps, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 24 months is close to that.

Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 19 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2022
First posted
Feb 21, 2022
StartActual
Feb 17, 2022
Primary completionActual
Mar 11, 2024
CompletionActual
Apr 2, 2024
Results first posted
Mar 26, 2025
Last update
Mar 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05248997
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 21, 2022
Start date
Feb 17, 2022
Primary completion
Mar 11, 2024
Completion
Apr 2, 2024
Results posted
Mar 26, 2025
Last update
Mar 26, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimegepant

Start the discussion